{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:48:29Z","timestamp":1778600909575,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703879"],"award-info":[{"award-number":["81703879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21904022"],"award-info":[{"award-number":["21904022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Commission of Health and Family Planning general project for clinical research of health industry","award":["201840377;201940449"],"award-info":[{"award-number":["201840377;201940449"]}]},{"name":"Putuo District of Shanghai Science And Technology Commission Research Project","award":["ptkwws201813"],"award-info":[{"award-number":["ptkwws201813"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20\u201330% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical significance to find noninvasive biomarkers to detect and predict NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aims of this study were to identify potential serum markers in individuals with early-stage NAFLD and to advance the mechanistic understanding of this disease using a high-throughput mass spectrometry-based untargeted metabolomics approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      One hundred and twelve patients with early-stage NAFLD aged 18\u201355 were recruited according to the guidelines. The control group included 112 healthy participants. The demographic, anthropometric, clinical and laboratory data of all participants were systematically collected. Serum samples were obtained after an overnight fast. The comprehensive serum metabolomic analysis was performed by ultra-performance liquid chromatography-Orbitrap mass spectrometry. The resultant data was processed by Compound Discover and SIMCA-P software to validate the potential biomarkers. Significantly altered metabolites were evaluated by variable importance in projection value (\n                      <jats:italic>VIP<\/jats:italic>\n                      \u2009&gt;\u20091) and ANOVA (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Pathway analysis was performed using MetaboAnalyst 4.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The liver function test of early NAFLD patients showed no statistical differences to control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u2009\n                      <jats:italic>0.05<\/jats:italic>\n                      ). However, obvious differences in blood lipids were observed between subjects with NAFLD and controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\n                      <jats:italic>0.001<\/jats:italic>\n                      ). In total, 55 metabolites showed significant changes in experimental group were identified. The area under curve (AUC) values deduced by receiver operating curve (ROC) analysis indicated that these newly identified biomarkers have high predictability and reliability. Of these, 15 metabolites with AUC greater than 0.9 were of great diagnostic value in early NAFLD patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, a total of 15 serum metabolites were found to strongly associate with early NAFLD. These biomarkers may have great clinical significance in the early diagnosis of NAFLD, as well as to follow response to therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-021-02820-7","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T10:48:47Z","timestamp":1618483727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry"],"prefix":"10.1186","volume":"19","author":[{"given":"Cheng","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanye","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"issue":"5","key":"2820_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71(5):1851\u201364.","journal-title":"Hepatology"},{"issue":"10","key":"2820_CR2","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/j.1440-1746.2012.07222.x","volume":"27","author":"CJ Liu","year":"2012","unstructured":"Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27(10):1555\u201360.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2820_CR3","doi-asserted-by":"publisher","first-page":"e0170758","DOI":"10.1371\/journal.pone.0170758","volume":"12","author":"W Hu","year":"2017","unstructured":"Hu W, Shao X, Guo D, et al. Relationship of serum betatrophin with nonalcoholic fatty liver in a chinese population. PLoS ONE. 2017;12(1):e0170758.","journal-title":"PLoS ONE"},{"issue":"12","key":"2820_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.11622\/smedj.2016189","volume":"58","author":"KB Khaw","year":"2017","unstructured":"Khaw KB, Choi RH, Kam JH, et al. Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population. Singap Med J. 2017;58(12):703\u20137.","journal-title":"Singap Med J"},{"issue":"10075","key":"2820_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S0140-6736(16)32380-7","volume":"389","author":"S Stringhini","year":"2017","unstructured":"Stringhini S, Carmeli C, Jokela M, et al. Socioeconomic status and the 25 \u00d7 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1\u00b77 million men and women. Lancet. 2017;389(10075):1229\u201337.","journal-title":"Lancet"},{"issue":"4","key":"2820_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"674","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW, et al. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;674(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"5","key":"2820_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/17474124.2018.1460202","volume":"12","author":"FB Lu","year":"2018","unstructured":"Lu FB, Hu ED, Xu LM, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Exp Rev Gastroenterol Hepatol. 2018;12(5):491\u2013502.","journal-title":"Exp Rev Gastroenterol Hepatol"},{"issue":"3","key":"2820_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"2820_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","volume":"10","author":"DL White","year":"2012","unstructured":"White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342-1359 e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2820_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","volume":"14","author":"S Mittal","year":"2016","unstructured":"Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124-131e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9724","key":"2820_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0140-6736(09)62195-4","volume":"375","author":"L Castera","year":"2010","unstructured":"Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet. 2010;375(9724):1419\u201320.","journal-title":"Lancet"},{"issue":"8","key":"2820_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.metabol.2016.01.013","volume":"65","author":"N Alkhouri","year":"2016","unstructured":"Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet? Metab Clin Exp. 2016;65(8):1087\u201395.","journal-title":"Metab Clin Exp"},{"issue":"8","key":"2820_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, De Ledinghen V, et al. Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"31","key":"2820_CR14","doi-asserted-by":"publisher","first-page":"10851","DOI":"10.3748\/wjg.v20.i31.10851","volume":"20","author":"E Fitzpatrick","year":"2014","unstructured":"Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol. 2014;20(31):10851\u201363.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2820_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen P, Kangas AJ, Wurtz P, et al. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8(1):192\u2013206.","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"2820_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/aje\/kwu143","volume":"180","author":"I Tzoulaki","year":"2014","unstructured":"Tzoulaki I, Ebbels TM, Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. Am J Epidemiol. 2014;180(2):129\u201339.","journal-title":"Am J Epidemiol"},{"key":"2820_CR17","first-page":"152865","volume":"58","author":"L Zhao","year":"2019","unstructured":"Zhao L, Zhang J, Pan L, et al. Protective effect of 7,3\u2019,4\u2019-flavon-3-ol (fisetin) on acetaminophen-induced hepatotoxicity in vitro and in vivo. Phytomed Int J Phytother Phytopharmacol. 2019;58:152865.","journal-title":"Phytomed Int J Phytother Phytopharmacol"},{"issue":"15","key":"2820_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3748\/wjg.v24.i15.1601","volume":"24","author":"CJ Pirola","year":"2018","unstructured":"Pirola CJ, Sookoian S. Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. World J Gastroenterol. 2018;24(15):1601\u201315.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2820_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4254\/wjh.v10.i3.371","volume":"10","author":"B Procopet","year":"2018","unstructured":"Procopet B, Fischer P, Farcau O, et al. Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease. World J Hepatol. 2018;10(3):371\u20138.","journal-title":"World J Hepatol"},{"key":"2820_CR20","unstructured":"National Workshop on Fatty liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Mdeical Association, et al. Guideline of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update. J Mod Med Health 2018;34(5):644\u2013645."},{"issue":"6","key":"2820_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.14309\/ajg.0000000000000607","volume":"115","author":"L Xu","year":"2020","unstructured":"Xu L, Xie J, Chen S, et al. Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: a nine-year cohort study. Am J Gastroenterol. 2020;115(6):876\u201384.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2820_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","volume":"50","author":"JG Fan","year":"2009","unstructured":"Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50(1):204\u201310.","journal-title":"J Hepatol"},{"issue":"11","key":"2820_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686\u201390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2820_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","volume":"29","author":"NC Leite","year":"2009","unstructured":"Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113\u20139.","journal-title":"Liver Int"},{"issue":"1","key":"2820_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajg.2014.01.008","volume":"15","author":"AO Almobarak","year":"2014","unstructured":"Almobarak AO, Barakat S, Khalifa MH, et al. Nonalcoholic fatty liver disease (NAFLD) in a Sudanese population: what is the prevalence and risk factors? Arab J Gastroenterol. 2014;15(1):12\u20135.","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"2820_CR26","first-page":"CD007340","volume":"1","author":"NC Chavez-Tapia","year":"2010","unstructured":"Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;1(1):CD007340.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2820_CR27","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2337\/dc10-0556","volume":"33","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota:the hygiene hypothesis expanded. Diabetes Care. 2010;33(10):2277\u201384.","journal-title":"Diabetes Care"},{"issue":"4","key":"2820_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.cld.2009.07.012","volume":"13","author":"AA Pillai","year":"2009","unstructured":"Pillai AA, Rinella ME. Non-alcoholic fatty liver disease:is bariatric surgery the answer? Clin Liver Dis. 2009;13(4):689\u2013710.","journal-title":"Clin Liver Dis"},{"issue":"10","key":"2820_CR29","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41395-018-0133-5","volume":"113","author":"T Mitchell","year":"2018","unstructured":"Mitchell T, Jefrey GP, de Boer B, et al. Type and pattern of alcohol consumption is associated with liver fbrosis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2018;113(10):1484\u201393.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2820_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","volume":"69","author":"Y Chang","year":"2019","unstructured":"Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69(1):64\u201375.","journal-title":"Hepatology"},{"issue":"2","key":"2820_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/hep.30226","volume":"70","author":"K Hajifathalian","year":"2019","unstructured":"Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology. 2019;70(2):511\u201321.","journal-title":"Hepatology"},{"issue":"8","key":"2820_CR32","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cgh.2013.11.038","volume":"12","author":"LH Nguyen","year":"2014","unstructured":"Nguyen LH, Chao D, Lim JK, et al. Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2014;12(8):1262\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2820_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1443-9573.2007.00286.x","volume":"8","author":"A Malik","year":"2007","unstructured":"Malik A, Cheah PL, Hilmi IN, et al. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. J Dig Dis. 2007;8(1):58\u201364.","journal-title":"J Dig Dis"},{"issue":"2","key":"2820_CR34","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.pbj.0000000000000031","volume":"4","author":"ASA Khammas","year":"2019","unstructured":"Khammas ASA, Hassan HA, Salih SQM, et al. Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study. Porto Biomed J. 2019;4(2):e31.","journal-title":"Porto Biomed J"},{"issue":"6","key":"2820_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4088\/JCP.09m05107yel","volume":"72","author":"X Fan","year":"2010","unstructured":"Fan X, Liu EY, Hoffman VP, et al. Triglyceride\/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia. J Clin Psy. 2010;72(6):806\u201312.","journal-title":"J Clin Psy"},{"issue":"4","key":"2820_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/egh.09.32","volume":"3","author":"N Alkhouri","year":"2009","unstructured":"Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Exp Rev Gastroenterol Hepatol. 2009;3(4):445\u201351.","journal-title":"Exp Rev Gastroenterol Hepatol"},{"issue":"4","key":"2820_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-725 e6.","journal-title":"Gastroenterology"},{"issue":"9","key":"2820_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jnutbio.2007.10.001","volume":"19","author":"CL Gentile","year":"2008","unstructured":"Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem. 2008;19(9):567\u201376.","journal-title":"J Nutr Biochem"},{"issue":"5","key":"2820_CR39","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/ijms20051220","volume":"20","author":"Y Xu","year":"2019","unstructured":"Xu Y, Han J, Dong J, et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development. Int J Mol Sci. 2019;20(5):1220\u201334.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2820_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1530\/EC-19-0023","volume":"8","author":"J Li","year":"2019","unstructured":"Li J, Zhao Y, Huang C, et al. Serum metabolomics analysis of the effect of exercise on nonalcoholic fatty liver disease. Endocr Connect. 2019;8(4):299\u2013308.","journal-title":"Endocr Connect"},{"issue":"1","key":"2820_CR41","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1038\/s41598-017-05040-6","volume":"7","author":"LN Tu","year":"2017","unstructured":"Tu LN, Showalter MR, Cajka T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep. 2017;7(1):6120.","journal-title":"Sci Rep"},{"key":"2820_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijbiomac.2019.01.141","volume":"128","author":"H Zhu","year":"2019","unstructured":"Zhu H, Wang Z, Wu Y, et al. Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease. Int J Biol Macromol. 2019;128:363\u201375.","journal-title":"Int J Biol Macromol"},{"issue":"6 Pt1","key":"2820_CR43","first-page":"E835","volume":"259","author":"GA Zello","year":"1990","unstructured":"Zello GA, Pencharz PB, Ball RO. Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L-[1\u201313C]phenylalanine. Am J Physiol. 1990;259(6 Pt1):E835\u201343.","journal-title":"Am J Physiol"},{"issue":"4","key":"2820_CR44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0002-9610(96)00392-3","volume":"173","author":"PA Burke","year":"1997","unstructured":"Burke PA, Stack JA, Wagner D, et al. L-[1-(13)C] Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg. 1997;173(4):270\u20133 (discussion 3-4).","journal-title":"Am J Surg"},{"issue":"11","key":"2820_CR45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s00535-003-1201-0","volume":"38","author":"Y Ishii","year":"2003","unstructured":"Ishii Y, Suzuki S, Kohno T, et al. Patients with severe liver cirrhosis followed up by L-[1-(13)C] phenylalanine breath test. J Gastroenterol. 2003;38(11):1086\u201390.","journal-title":"J Gastroenterol"},{"issue":"4","key":"2820_CR46","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1373\/clinchem.2006.081257","volume":"53","author":"Y Chang","year":"2007","unstructured":"Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53(4):686\u201392.","journal-title":"Clin Chem"},{"issue":"15","key":"2820_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJM196910092811503","volume":"281","author":"P Felig","year":"1969","unstructured":"Felig P, Marliss E, Cahill GF. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281(15):811\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"2820_CR48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1381\/096089203322190853","volume":"13","author":"M Moretto","year":"2003","unstructured":"Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obesity Surg. 2003;13(4):622\u20134.","journal-title":"Obesity Surg"},{"key":"2820_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.abb.2015.08.003","volume":"589","author":"DO Mook-Kanamori","year":"2016","unstructured":"Mook-Kanamori DO, de Mutsert R, Rensen PC, et al. Type 2 diabetes is associated with postprandial amino acid measures. Arch Biochem Biophys. 2016;589:138\u201344.","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"2820_CR50","doi-asserted-by":"publisher","first-page":"E463","DOI":"10.1210\/jc.2014-2357","volume":"100","author":"ND Palmer","year":"2015","unstructured":"Palmer ND, Stevens RD, Antinozzi PA, et al. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab. 2015;100(3):E463-468.","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1186\/s12967-021-03223-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-021-02820-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:05:27Z","timestamp":1666731927000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-02820-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2820"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-02820-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-134998\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-021-03223-4","URL":"https:\/\/doi.org\/10.1186\/s12967-021-03223-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was approved by the Human Ethics Committee of Putuo Hospital. Written informed consent was obtained from individual or guardian participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication has been obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}